CD19 and lymphoma: In 2022, CRISPR Therapeutics incorporation published the results of their Phase I clinical trial in the United States of two allogeneic CAR-T therapies targeting CD70 for the treatment of certain lymphomas and certain solid tumours, as well as CD19 for the treatment of leukaemia and lymphoma.